Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category

Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of ...
CoinDesk

BMW Taps JPMorgan for First Onchain Programmable FX Payment

BMW’s German and U.S. treasury teams pre-defined conditions through JPMorgan’s Programmable Payments application, which ...

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for ...